22nd Century Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that 22nd Century Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $25.83M | Mar 11, 2020 |
| FY2018 | Dec 31, 2018 | $7.13M | Mar 6, 2019 |
| FY2018 | Sep 30, 2018 | $6.26M | Mar 6, 2019 |
| FY2018 | Jun 30, 2018 | $6.91M | Mar 6, 2019 |
| FY2018 | Mar 31, 2018 | $6.12M | Mar 6, 2019 |
| FY2018 | Dec 31, 2017 | $5.94M | Mar 6, 2019 |
| FY2018 | Sep 30, 2017 | $4.53M | Mar 6, 2019 |
| FY2018 | Jun 30, 2017 | $3.90M | Mar 6, 2019 |
| FY2018 | Mar 31, 2017 | $2.23M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $3.34M | Mar 7, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $7.36M | Mar 28, 2024 |
| FY2023 | Sep 30, 2023 | $7.87M | Mar 28, 2024 |
| FY2023 | Jun 30, 2023 | $8.05M | Mar 28, 2024 |
| FY2023 | Mar 31, 2023 | $8.93M | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | $9.95M | Mar 28, 2024 |
| FY2023 | Sep 30, 2022 | $11.54M | Mar 28, 2024 |
| FY2023 | Jun 30, 2022 | $9.97M | Mar 28, 2024 |
| FY2023 | Mar 31, 2022 | $9.05M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $6.81M | Mar 9, 2023 |
| FY2022 | Sep 30, 2021 | $8.37M | Mar 9, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $242.7K | Feb 18, 2016 |
| FY2015 | Dec 31, 2014 | $447.5K | Feb 18, 2016 |
| FY2013 | Dec 31, 2013 | $7.28M | Jan 30, 2014 |
| FY2013 | Dec 31, 2012 | $18.8K | Jan 30, 2014 |
| FY2012 | Dec 31, 2011 | $788.6K | Mar 18, 2013 |
| FY2011 | Dec 31, 2010 | $49.8K | Apr 16, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $224.7K | Mar 11, 2020 |
| FY2019 | Sep 30, 2019 | ($21.1K) | Mar 11, 2020 |
| FY2019 | Jun 30, 2019 | ($86.3K) | Mar 11, 2020 |
| FY2019 | Mar 31, 2019 | ($102.9K) | Mar 11, 2020 |
| FY2019 | Dec 31, 2018 | $514.7K | Mar 11, 2020 |
| FY2019 | Sep 30, 2018 | $150.9K | Mar 11, 2020 |
| FY2019 | Jun 30, 2018 | $161.7K | Mar 11, 2020 |
| FY2019 | Mar 31, 2018 | $71.6K | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $71.4K | Mar 6, 2019 |
| FY2018 | Sep 30, 2017 | ($340.4K) | Mar 6, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.05M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($15.16M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($140.78M) | Mar 20, 2025 |
| FY2022 | Dec 31, 2022 | ($8.92M) | Mar 9, 2023 |
| FY2022 | Sep 30, 2022 | ($11.50M) | Mar 9, 2023 |
| FY2022 | Jun 30, 2022 | ($13.10M) | Mar 9, 2023 |
| FY2022 | Mar 31, 2022 | ($26.28M) | Mar 9, 2023 |
| FY2022 | Dec 31, 2021 | ($5.03M) | Mar 9, 2023 |
| FY2022 | Sep 30, 2021 | ($4.17M) | Mar 9, 2023 |
| FY2022 | Jun 30, 2021 | ($9.44M) | Mar 9, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.57M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($13.95M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($44.93M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($33.64M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($28.41M) | Mar 9, 2023 |
| FY2020 | Dec 31, 2020 | ($6.25M) | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | ($4.04M) | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | ($4.75M) | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | ($4.14M) | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | ($5.55M) | Mar 11, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $688.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.13M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.64M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.58M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.91M | Mar 9, 2023 |
| FY2019 | Dec 31, 2019 | $8.06M | Mar 11, 2020 |
| FY2019 | Dec 31, 2018 | $14.99M | Mar 11, 2020 |
| FY2019 | Dec 31, 2017 | $3.37M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $2.34M | Mar 6, 2019 |
| FY2017 | Dec 31, 2015 | $1.57M | Mar 7, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.59M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $10.29M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $31.06M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $32.23M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $25.91M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $14.97M | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | $12.95M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $8.59M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $8.28M | Mar 11, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.72M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($14.35M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($54.99M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($51.71M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($22.84M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($15.62M) | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | ($14.59M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($17.85M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | ($12.07M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | ($9.89M) | Mar 6, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $141.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $4.66M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.66M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $745.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $54.0K | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | $527.0K | Mar 1, 2022 |
| FY2015 | Dec 31, 2015 | $0 | Feb 18, 2016 |
| FY2015 | Dec 31, 2014 | $0 | Feb 18, 2016 |
| FY2015 | Dec 31, 2013 | $457.7K | Feb 18, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.02M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $21.67M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $27.50M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $114.65M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $75.95M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $51.69M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $68.95M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $77.30M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $79.74M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $27.64M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.53M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $17.66M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $35.91M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $18.68M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $9.88M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $7.58M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $6.90M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $6.02M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $4.31M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $3.31M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.76M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.01M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | ($8.41M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $95.98M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $66.07M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $44.11M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $62.05M | Mar 1, 2022 |
| FY2021 | Dec 31, 2018 | $71.28M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $75.42M | Mar 11, 2021 |
| FY2019 | Dec 31, 2016 | $24.33M | Mar 11, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $0 | Mar 20, 2025 |
| FY2022 | Dec 31, 2022 | $33.16M | Mar 9, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($398.93M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($393.87M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($378.71M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($237.81M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($178.01M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($145.40M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($125.69M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($99.13M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($91.17M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($78.14M) | Mar 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.15M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.42M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.06M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.21M | Mar 28, 2024 |
| FY2019 | Dec 31, 2019 | $485.1K | Mar 11, 2020 |
| FY2019 | Dec 31, 2018 | $604.9K | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $3.66M | Mar 6, 2019 |
| FY2018 | Dec 31, 2016 | $13.47M | Mar 6, 2019 |
| FY2018 | Dec 31, 2015 | $3.76M | Mar 6, 2019 |
| FY2017 | Dec 31, 2014 | $6.40M | Mar 7, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $708.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.67M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $13.91M | Mar 20, 2025 |
| FY2022 | Dec 31, 2022 | $3.91M | Mar 9, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (52) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (45,711) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (15,925) | Mar 20, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 9, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Mar 9, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 9, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Mar 9, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Mar 9, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Mar 9, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (52) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (45,711) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (15,925) | Mar 20, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 9, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Mar 9, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 9, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Mar 9, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Mar 9, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Mar 9, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 510,384 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 2,285 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 20,313 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 14.35M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 162.87M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 139.06M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 138.36M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 124.64M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | 123.57M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 90.70M | Mar 7, 2018 |